RNA Interference Therapy for Resistant Hypertension: How a Twice-Yearly Injection Could Replace Daily Pills

What Is RNA Interference Therapy for Blood Pressure?

Unlike traditional antihypertensives that block receptors or inhibit enzymes downstream, RNA interference therapy targets the problem at its genetic source. Zilebesiran, an investigational subcutaneous injection developed by Alnylam Pharmaceuticals, uses small interfering RNA (siRNA) to reduce the liver's production of angiotensinogen — the precursor protein that feeds into the renin-angiotensin-aldosterone system (RAAS), the body's primary blood pressure regulation pathway.

The approach is particularly significant for patients with treatment-resistant hypertension, defined as blood pressure that remains above target despite the use of three or more antihypertensive medications at optimal doses, including a diuretic. According to estimates from the American Heart Association, roughly 10 to 15 percent of people with hypertension fall into this category, leaving them at substantially elevated risk of stroke, heart attack, and kidney failure.

How Does Zilebesiran Differ From Existing Blood Pressure Medications?

Conventional blood pressure medications — ACE inhibitors, angiotensin receptor blockers (ARBs), calcium channel blockers, and diuretics — all act at different points downstream in the RAAS pathway. Zilebesiran intervenes at the very top of this cascade, reducing the supply of angiotensinogen before it can be converted to angiotensin I and subsequently angiotensin II, the potent vasoconstrictor responsible for raising blood pressure.

The clinical trial program known as KARDIA has been evaluating zilebesiran in multiple phases. Results from these trials have shown sustained blood pressure reductions over six-month dosing intervals. This long-acting profile could address one of the most persistent challenges in hypertension management: medication adherence. Research published in the journal Circulation has consistently shown that roughly half of patients prescribed daily antihypertensives stop taking them within a year, a major contributor to uncontrolled blood pressure worldwide.

The World Health Organization estimates that hypertension affects approximately 1.28 billion adults globally, yet only about one in five has it under adequate control. A treatment requiring just two injections per year could fundamentally change the adherence equation for millions of patients.

Who Could Benefit From This New Treatment Approach?

The most immediate beneficiaries would be patients with confirmed treatment-resistant hypertension — those already taking three or more medications without reaching their blood pressure goals. For these individuals, adding yet another daily pill often yields diminishing returns and increases the burden of side effects. An RNAi approach that works through a completely different mechanism offers a genuinely new therapeutic option.

Beyond resistant hypertension, the long-acting nature of the injection could also benefit patients who struggle with daily medication routines due to cognitive decline, complex multi-drug regimens for other conditions, or socioeconomic barriers to consistent pharmacy access. However, the therapy is still under regulatory review, and questions remain about long-term safety, cost, and how it will fit into existing treatment guidelines. Clinicians will need to weigh the benefits of sustained blood pressure control against the fact that the drug's effects cannot be quickly reversed if adverse reactions occur.